Галерея 3154959

Галерея 3154959

Clipboard, Search History, and several other advanced features are temporarily unavailable.

Dashboard
Publications
Account settings
Log out

Advanced

Clipboard

Format

Abstract

PubMed

PMID

Format:

Summary (text)
PubMed
PMID
Abstract (text)
CSV

Subject:

1 selected item: 3154959 - PubMed

Format:

Summary
Summary (text)
Abstract
Abstract (text)

Create a new collection

Add to an existing collection

Name must be less than 100 characters

Unable to load your collection due to an error
Please try again

Unable to load your delegates due to an error
Please try again

Would you like email updates of new search results?

Saved Search Alert Radio Buttons

Yes

No

Frequency:

Monthly
Weekly
Daily

Which day?

The first Sunday
The first Monday
The first Tuesday
The first Wednesday
The first Thursday
The first Friday
The first Saturday
The first day
The first weekday

Which day?

Sunday
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday

Report format:

Summary
Summary (text)
Abstract
Abstract (text)
PubMed

Send at most:

1 item
5 items
10 items
20 items
50 items
100 items
200 items

Send even when there aren't any new results

Number of items displayed:

5
10
15
20
50
100

Create a new collection Add to an existing collection

Name must be less than 100 characters

Unable to load your collection due to an error Please try again

Page navigation

Title & authors

Abstract

Similar articles

Publication types

MeSH terms

Substances

Related information

Affiliation

1 Division of Biological, Environmental, and Medical Research, Argonne National Laboratory, Illinois 60439-4833.

J Taylor et al.

Appl Theor Electrophor .

1988 .

Format

Abstract

PubMed

PMID

Affiliation

1 Division of Biological, Environmental, and Medical Research, Argonne National Laboratory, Illinois 60439-4833.

Berkelman T.
Berkelman T.
Methods Mol Biol. 2008;424:51-62. doi: 10.1007/978-1-60327-064-9_5.
Methods Mol Biol. 2008.

PMID: 18369852

Review.

Bukalis K, Wolf C, Behne D, Kyriakopoulos A.
Bukalis K, et al.
J Chromatogr A. 2007 Jul 6;1155(2):180-6. doi: 10.1016/j.chroma.2007.01.094. Epub 2007 Feb 1.
J Chromatogr A. 2007.

PMID: 17306817

Pasquali C, Fialka I, Huber LA.
Pasquali C, et al.
Electrophoresis. 1997 Dec;18(14):2573-81. doi: 10.1002/elps.1150181413.
Electrophoresis. 1997.

PMID: 9527487

Wang YC, Choi MH, Han J.
Wang YC, et al.
Anal Chem. 2004 Aug 1;76(15):4426-31. doi: 10.1021/ac0497499.
Anal Chem. 2004.

PMID: 15283583

Ahmed N, Rice GE.
Ahmed N, et al.
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):39-50. doi: 10.1016/j.jchromb.2004.10.070.
J Chromatogr B Analyt Technol Biomed Life Sci. 2005.

PMID: 15652797

Review.

Related information

MedGen

Format:

AMA

APA

MLA

NLM

Send To

Clipboard

Email
Save

My Bibliography
Collections

Citation Manager

[x]

NLM

NIH

HHS

USA.gov

An official website of the United States government

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.

The site is secure.

The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.

Protein samples submitted for routine separation and analysis by two-dimensional electrophoretic techniques are often a mixture of proteins from different species, cell types, subcellular components, or even unknown contaminants. Varying amounts of individual components can account for many of the major effects seen in an experiment and can mask other, more subtle changes. This paper presents methods for estimating the percentages of these components in a mixture and procedures for correcting for their presence. The methods are tested by using a simple data set composed of differing amounts of two pure fractions.

MeSH
PMC
Bookshelf
Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Help
Accessibility
Careers

PT3154959T

true
PT3154959T
( pt )

PT15726455T

PT3154959T
( pt )

1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka

Pyrazolo[1,5-]pyrimidine compound as trk kinase inhibitor

Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa

Compuestos macrocíclicos como inhibidores de la Trk cinasa

Urea derivative or pharmacologically acceptable salt thereof

Molecules for administration to ROS1 mutant cancer cells

（Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形

ロクソオンコロジー，インコーポレイテッドＬｏｘｏＯｎｃｏｌｏｇｙ，Ｉｎｃ．

WO2017006953A1
( ja )

*

Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer

Point mutations in Trk inhibitor-resistant cancer and methods relating to the same

Nitrogen-containing heterocycle and carbocycle derivatives having trka inhibitory activity

Methods of treating pediatric cancers

Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Methods of treating pediatric cancers

Preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-A)pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide

مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret

مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret

عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها

مركبات حلقية ضخمة كمثبطات لكيناز ros1

Novel tetrahydronaphthyl urea derivatives

CN107245073B
( zh )

*

Pharmaceutical compositions and dosage forms

JP2019026646A
( ja )

*

含窒素複素環および炭素環誘導体を含有する、疼痛の治療および／または予防用医薬組成物

EP3661935B1
( en )

*

Substituted pyrazolopyrimidines useful as kinases inhibitors

6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物

PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS

Formulations d'un inhibiteur de kinase trk macrocyclique

Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors

Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors

Phenylpyrrolidinone formyl peptide 2 receptor agonists

Treatment of trk-associated cancers

CN108794484B
( zh )

*

[1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用

(s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제

Fused heterocyclic compounds as ret kinase inhibitors

WO2020083377A1
( zh )

*

Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases

A dbait molecule in combination with kinase inhibitor for the treatment of cancer

Institut National de la Santé et de la Recherche Médicale (INSERM)
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors

WO2021139794A1
( zh )

*

WO2022218289A1
( en )

*

Tropomyosin receptor kinase (trk) degradation compounds and methods of use

Azole derivatives, their use, production and usage

Pyrazole derivatives and their pharmaceutical use

Inhibitors of factor Xa with a neutral P1 specificity group

Boehringer Ingelheim Pharmaceuticals, Inc.
Aromatic heterocyclic compounds as anti-inflammatory agents

INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer

Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas

Boehringer Ingelheim Pharmaceuticals Inc.
Aromatična hetrerociklična jedinjenja kao antiinflamatorni agensi

3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents

Benzylcycloalkyl amines as modulators of chemokine receptor activity

Bristol-Myers Squibb Pharma Company
N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity

Pyrazolamide zur anwendung in der behandlung von schmerz

New neuropeptide y y5 receptor antagonists

Способы лечения послеоперационной боли введением антагониста фактора роста нервов и композиции, содержащие фактор роста нервов

Medicaments for the treatment of neurodegenerative disorders or diabetes

Modulation of protein functionalities

Kondensierte verbindungen, die den vanilloid receptor subtype 1 (vr1)-rezeptor hemmen

Urea derivatives as FLT-3 modulators

Modulation of protein functionalities

光学活性ｔｒａｎｓ−４−アミノ−１−ベンジル−３−ピロリジノールの製造方法

Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors

Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases

Novel hetero pyrrole analogs acting on cannapinoid receptors

Thienopyrimidine and thienopyridine kinase modulators

Pyrazolyl urea derivatives useful in the treatment of cancer

Urea compounds useful in the treatment of cancer

Serotonin transporter (SERT) inhibitors

Aminopiperidines and realted compounds

Chemical process for preparation of intermediates

Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Kinase inhibitors useful for the treatment of proliferative diseases

Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases

Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases

Combination therapies for treatment of cancer and inflammatory diseases

Nuovi derivati ureici dell'acido 1h-pirazol-4-carbossilico con attivita inibente nei confronti della chemiotassi di neutrofili

Takeda Pharmaceutical Company Limited
Nitrogen-containing heterocyclic compound and use of same

Derivados de pirrolidina n-bencilo.

Pyrazolo[1,5-]pyrimidine compound as trk kinase inhibitor

Derivados de 1-arilpirazol diméricos

Urea derivatives having pi3k-inhibiting activity

Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa

Selective calcium channel modulators

Compuestos macrocíclicos como inhibidores de la Trk cinasa

PL2712358T3
( pl )

*

Związki mocznika pirolidynowego, tiomocznika pirolidynowego oraz guanidyny pirolidynowej jako inhibitory kinazy trka

Novel compounds that are erk inhibitors

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Novel compounds that are ERK inhibitors

Novel compounds that are erk inhibitors

N-pirrolidinil-, N'-pirazolil-karbamid, tiokarbamid, guanidin és cianoguanidin vegyületek mint TrkA kináz inhibitorok

Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors

Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю

Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors

N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze

מלחים של 1–((4–מתוקסימתיל)–4–(((s2,r1) –2–פניל–ציקלופרופילאמין) מתיל) פיפרידין–1–איל)מתיל)– ציקלובוטאן–חומצה קארבוקסילית כמעכבי lsd1

תרכובות 2–(4–אמינוציקלוהקסילאמינו)–4–(פיראזול–4–יל)פירימידין

פיפרדינים –(3,5 דו–מותמר–פירידין –4 –יל)–1

Novel 2,5-substituted pyrimidines as pde inhibitors

אמינוטריאזולופירידינים כמעכבי קינאז

אמינואימידאזופירידאזינים כמעכבי קינאז

Spak kinase inhibitors as neuroprotective agents

Kristalne oblike 1-((2R,4R)-2-(1H-benzo(D)imidazol-2-IL)-1-metilpiperidin-4-IL)-3-(4- cianofenil)urea maleata

用於取代的 -芐基- 異噁唑- -基甲基 -吡唑- -基咪唑烷- -二酮的合成的改進方法

Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf

(2–5–(r4 ,s (5'–כלורו–2'–פלואורוביפניל–4–איל)–4–(אתוקסיאוקסאלילאמינו)–2–הידרוקסימתיל–2–חומצה מתילפנטנואית כמעכב נפריליסין

N–((4r,3s)–1–(8–כלורוקינוקסלין–6–איל)קרבוניל)–3–(4–פלואורופניל)–פיפרידין–4–איל)–1–מתיל–5–(טריפלואורומתיל)–1h–פירזול–3–קרבוקסאמיד ושימוש רפואי שלו

Learn how to leverage transparent company data at scale.
Subscribe to our emails

The Open Database Of The Corporate World

Company Number 3154959

Status Active
Incorporation Date 7 July 2003 (over 19 years ago)

Company Type Business Corporation
Jurisdiction Pennsylvania (US)

Branch Branch of J.F. HILLEBRAND USA, INC. (Delaware (US))

Бляди есть чем развлечь себя в туалете
Длинноволосую красивую брюнетку пацан ебет в рот а потом ставит раком
Сиськи без силикона Николь

Галерея 3154959

Report Page